Get started
Author

Joseph J. Otto

ORCID: 0000-0003-4157-5559
Observed ORCID: 0000-0003-4157-5559
OpenAlex ID: A5010734112
Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in‐depth proteomic analysis
2022 · Vanessa L. Correll, Joseph J. Otto, et al. · Journal of Extracellular Vesicles · 63
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
2024 · Chang-Ching Lin, Tsung-Cheng Chang, et al. · Nature Communications · 50
PDF
Reinspection of a Clinical Proteomics Tumor Analysis Consortium (CPTAC) Dataset with Cloud Computing Reveals Abundant Post-Translational Modifications and Protein Sequence Variants
2021 · Amol Prakash, Lorne Taylor, et al. · Cancers · 13
PDF
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post‐DRE Urines for Quantitation and Genotype Determination
2020 · Joseph J. Otto, Vanessa L. Correll, et al. · PROTEOMICS - CLINICAL APPLICATIONS · 11
PDF
Gut immunoglobulin alpha anti-glycan binding profiles as a research tool for local disease detection
2018 · Joseph J. Otto, Crystal L. Daniels, et al. · Glycoconjugate Journal · 2
Insulin receptor substrate 4 deficiency mediates the insulin effect on the epithelial magnesium channel TRPM6 and causes hypomagnesemia
2022 · Jing Zhang, Sung Wan An, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract 3008: PSMA glycosylation and aggressive prostate cancer progression
2019 · Tanya C. Burch, Stephen S. Mackay, et al. · Cancer Research · 1
Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer
2023 · Chang-Ching Lin, Tsung-Cheng Chang, et al. · Cancer Research
Abstract 3008: PSMA glycosylation and aggressive prostate cancer progression
2019 · Tanya C. Burch, Stephen S. Mackay, et al. · Clinical Research (Excluding Clinical Trials)
Works count: 9
Citation count: 140
H-index: 4
I10-index: 4
Year
Topic
Type